

# Course

A DSBS Two-day Training Course

## Health Technology Assessment Submissions and Statisticians

26 and 27 May 2014 at Højstrupgård, Helsingør

Day 1: Challenges of HTA and why we should be involved. Case stories from around Europe.

Evening: Dinner and Quadrille dance

Day 2: Software practicum on Network Meta-Analysis in SAS

**Registration by 12 May 2014 to [Lisbeth.Bille@leo-pharma.com](mailto:Lisbeth.Bille@leo-pharma.com)**

Health Technology Assessment is a multidisciplinary field of policy analysis. While we are used to working with the regulatory perspective to demonstrate efficacy and safety, the HTA perspective goes further to examine clinical and cost effectiveness.

For Europe, we have one standard for drug approval, one application, one assessment and one decision valid in 28 EU + 3 EFTA countries. When facing negotiations with payers for reimbursement, there are 30+ different HTA methodologies and interpretations as well as 40+ independent decisions about whether the medicine should be paid for in Europe.

This evolving area which requires direct involvement from statisticians will be introduced. Case stories from around Europe will be presented. The first day will lastly discuss the trends and perspectives. Day 2 will be 'hands on' and focus on statistical techniques and available software to perform analyses that support a HTA. You will need to have SAS (and optionally Winbugs) on your laptop in order to complete the different exercises.

To bridge the two days, we will enjoy dinner and some fun in the evening. Hotel accommodation available. Price: 5000 kr. for both days with dinner and accommodation. 1000 kr. for the first day. 1000 kr. for dinner.



*Dansk Selskab for Biofarmaceutisk Statistik*

Formand:

Kristian Windfeld

H. Lundbeck A/S, Ottiliavej 9, 2500 Valby

Tlf.: 3630 1311; Fax: 3643 8263

E-mail: [krwi@lundbeck.com](mailto:krwi@lundbeck.com)

## *Program* (detailed program will be presented later)

Day 1	Introduction to HTA from a Health Economics and a Statistics point of view will be followed by HTA case stories from the pharmaceutical and device industry from UK, Scotland, Germany and Denmark. Finally, perspectives on HTA including the role of statisticians in the future will be attempted to be defined.
	DSBS General Meeting
	Evening with Dinner and Quadrille dance
Day 2	<p>Software practical workshop on Network Meta-analysis</p> <p>The motivation for the usage will be explained together with case stories. These will include analyses of binary, multinomial, ordinal and time to event data as well as considerations of fixed and random effects, covariable regression and explicit modeling of consistency.</p> <p>The statistical models and underlying assumptions will be explained. The models will be fitted both within a frequentist and a Bayesian framework, contrasting the two. The course will include SAS code for both approaches as well as equivalent WinBUGS code for the latter. A summary of the methodology that appears in the literature will be provided, including recommended best practices for the presentation and interpretation of network meta-analyses.</p>

## *Speakers and Instructors*

Karen Facey, NHS Health Scotland

Neil Hawkins, Global Health Economics, ICON, UK

David Scott, Global Health Economics, ICON, UK

Oliver Macheleidt, Health Outcomes Research, LEO Germany

Martin Strandberg-Larsen, Health Economics, Novo Nordisk, External Lecturer, University of Copenhagen

David Antony Tyas, Lundbeck, France

Martin Nottmeier, Health Economist, Coloplast, Denmark



**Dansk Selskab for Biofarmaceutisk Statistik**

Formand:

Kristian Windfeld

H. Lundbeck A/S, Ottiliavej 9, 2500 Valby

Tlf.: 3630 1311; Fax: 3643 8263

E-mail: [krwi@lundbeck.com](mailto:krwi@lundbeck.com)